Hot Topics | Published:

Tinkering with THC-to-CBD ratios in Marijuana

Neuropsychopharmacologyvolume 44pages215216 (2019) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    De Aquino JP, Sherif M, Radhakrishnan R, Cahill JD, Ranganathan M, D’Souza DC. The psychiatric consequences of Cannabinoids. Clin Ther. 2018.

  2. 2.

    ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in cannabis potency over the last 2 decades (1995-2014): analysis of current data in the United States. Biol Psychiatry. 2016;79:613–9.

  3. 3.

    Boggs DL, Nguyen JD, Morgenson D, Taffe MA, Ranganathan M. Clinical and preclinical evidence for functional interactions of cannabidiol and Δ(9)-Tetrahydrocannabinol. Neuropsychopharmacology. 2018;43:142–54.

  4. 4.

    Englund A, Freeman TP, Murray RM, McGuire P. Can we make cannabis safer? Lancet Psychiatry. 2017;4:643–8.

  5. 5.

    National Academies of Sciences, Engineering, Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research, January 2017. http://nationalacademies.org/hmd/Reports/2017/health-effects-of-cannabis-and-cannabinoids.aspx; http://nationalacademies.org/hmd/~/media/Files/Report%20Files/2017/Cannabis-Health-Effects/Cannabis-chapter-highlights.pdf.

  6. 6.

    Morgan CJA, Curran HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry. 2008;192:306–7.

  7. 7.

    Schubart CD, Sommer IE, van Gastel WA, Goetgebuer RL, Kahn RS, Boks MP (2011). Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res. 2011;130:216–21.

  8. 8.

    Madras BK, Bergman J, Kohut S, George S, Hurd Y, Lin Z. THC of marijuana upregulates dcc mRNA expression in prefrontal cortex but THC combined with Cannabidiol (CBD) does not: relevance to psychiatric symptoms associated with long term marijuana use? American College of Neuropsychopharmacology 56th Annual Meeting. Palm Springs, CA, 3–7 Dec 2016: Poster T234; 2017.

Download references

Acknowledgements

The author thanks her indispensable collaborators Dr. Susan George, Dr. Jack Bergman, Dr. Stephen Kohut, Dr. Sarah Withey, Dr. Zhicheng Lin, Dr. Yasmin Hurd, Dr. A. Hasbi, and students Sophia Charles and Andrew Gumbert.

Funding

The research is funded by a grant from the NIH-National Institute on Drug Abuse NIDA: DA042178. The author receives funding for specific speaking engagements focused on the public health challenges of drugs of abuse and solutions.

Author information

Affiliations

  1. McLean Hospital and Department of Psychiatry, Harvard Medical School, Belmont, MA, 02478, USA

    • Bertha K. Madras

Authors

  1. Search for Bertha K. Madras in:

Competing interests

The author declares no competing interest.

Corresponding author

Correspondence to Bertha K. Madras.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/s41386-018-0217-3